Banisadre M, Ala F, Modjtabai A, Dutz W, Navab F
Cancer. 1985 Sep 15;56(6):1384-91. doi: 10.1002/1097-0142(19850915)56:6<1384::aid-cncr2820560628>3.0.co;2-5.
Forty-three patients with immunoproliferative small intestinal disease and primary small intestinal lymphoma were studied prospectively. Eighteen patients in whom alpha-chain protein was detected in the serum had significantly more features of malabsorption, and disease was localized more commonly in the jejunum. In all of these patients, a diffuse lymphoplasmacytic infiltrate was found in the intestine; in three patients lymphoma was found only in mesenteric lymph nodes. Twenty-five patients with lymphoma in whom alpha-chain protein failed to be detected had significantly more features of intestinal obstruction, and disease was found more commonly in the ileum. Five of these patients had lymphoma associated with a diffuse mucosal infiltrate that was indistinguishable from the first group. In patients available for follow-up, no difference was found in cumulative survival over 30 months in the two groups, with approximately 40% mortality at 6 months.
对43例免疫增殖性小肠疾病和原发性小肠淋巴瘤患者进行了前瞻性研究。血清中检测到α链蛋白的18例患者有明显更多的吸收不良特征,且疾病更常见于空肠。在所有这些患者中,肠道均发现弥漫性淋巴浆细胞浸润;3例患者仅在肠系膜淋巴结发现淋巴瘤。25例未检测到α链蛋白的淋巴瘤患者有明显更多的肠梗阻特征,且疾病更常见于回肠。其中5例患者的淋巴瘤伴有弥漫性黏膜浸润,与第一组难以区分。在可进行随访的患者中,两组30个月的累积生存率无差异,6个月时死亡率约为40%。